FT Options’s Novavax NVAX Stock Holding History

FT Options’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,500	Closed	-$187K	–	337
2016 Q3	$187K	Buy	+4,500	New	+$581K	0.15%	109

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QIM

Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FT Options's NVAX Position: Q4 2016 in Review

FT Options sold out of Novavax (NVAX) in Q4 2016, closing a stake of 4,500 shares — an estimated $187K sold.

FT Options first reported a position in NVAX in Q3 2016 and held it in 1 quarter. The position peaked at $187K in Q3 2016. 142 funds tracked by Wall St. Rank hold NVAX as of Q4 2016.

FT Options reported no remaining Novavax position as of Q4 2016 after selling out during the quarter.
FT Options sold 4,500 Novavax shares in Q4 2016, an estimated $187K.
FT Options first reported a position in Novavax in Q3 2016 and held it in 1 quarter.
FT Options's Novavax position peaked at $187K in Q3 2016.
142 funds tracked by Wall St. Rank held Novavax as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.